DelveInsight’s, “Antibody Drug Conjugate Competitive Landscape, 2023,” report provides comprehensive insights about 180+ Antibody Drug Conjugate companies and 290+ Antibody Drug Conjugate drugs in Antibody Drug Conjugate Competitive landscape. It covers the Antibody Drug Conjugate pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ADC pipeline products in this space.
Key Takeaways from the Antibody Drug Conjugate Pipeline Report
- DelveInsight’s Antibody Drug Conjugate pipeline report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
- The leading companies working in the Antibody Drug Conjugate Market include NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
- Promising Antibody Drug Conjugate Pipeline Therapies in the various stages of development include Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
- December 2023: Unicancer announced a drug which is named DS-8201a in the clinical trials of phase 2. Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
- December 2023: Daiichi Sankyo Inc. announced a drug which is named Ifinatamab Deruxtecan (I-DXd) in the clinical trials of phase 2. This study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum 3 prior lines of therapy and to investigate I-DXd anti-tumor activity in this population.
Request a sample and discover the recent advances in Antibody Drug Conjugate Drugs @ Antibody Drug Conjugate Competitive Landscape Report
The Antibody Drug Conjugate Pipeline Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Overview
Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components.
Find out more about Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment @ Antibody Drug Conjugate Collaboration Analysis by Companies
Antibody Drug Conjugate Pipeline Therapies and Companies
- Jiangsu Hengrui Medicine Co Ltd.: SHR-A1811
- Seagen Inc.: Ladiratuzumab Vedotin
- ImmunoGen Inc.: IMGN151
- Daiichi Sankyo: DS-6000
Antibody Drug Conjugate Pipeline Analytical Perspective
The Antibody Drug Conjugate pipeline report provides in-depth commercial assessment of Antibody Drug Conjugate drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Antibody Drug Conjugate Pipeline Report Assessment
- Antibody Drug Conjugate Company Analysis
- Antibody Drug Conjugate Pipeline Therapeutic Assessment
- Antibody Drug Conjugate Pipeline Assessment
- Inactive Antibody Drug Conjugate drugs assessment
- Antibody Drug Conjugate Unmet Needs
Learn more about the emerging Antibody Drug Conjugate Competitive Landscape @ Antibody Drug Conjugate Market Drivers and Barriers, Unmet Needs
Scope of the Antibody Drug Conjugate Competitive Landscape Report
- Coverage- Global
- Antibody Drug Conjugate Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
- Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
- Antibody Drug Conjugate Pipeline Therapies- Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
Dive deep into rich insights for new drugs for Antibody Drug Conjugate Product Developmental Activities, Visit @ Antibody Drug Conjugate Research and Development Activities
Table of Content
- Introduction
- Antibody Drug Conjugate Executive Summary
- Antibody Drug Conjugate Overview
- Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
- Antibody Drug Conjugate Competitive Landscape
- Antibody Drug Conjugate Therapeutic Assessment
- Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
- Pfizer
- MYLOTARG
- Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
- Late Stage Products (Phase III)
- ADC Therapeutics
- Zynlonta
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Seagen Inc.
- Ladiratuzumab Vedotin
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ImmunoGen, Inc.
- IMGN151
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Company Name
- Product Name
- Drug profiles in the detailed report…..
- Inactive Products
- Antibody Drug Conjugate – Unmet needs
- Antibody Drug Conjugate– Market drivers and barriers
- Appendix
For further information on the Antibody Drug Conjugate Report @ Antibody Drug Conjugate Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market